First Eagle Investment Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-146,402
Closed -$56K 341
2017
Q4
$56K Hold
146,402
﹤0.01% 294
2017
Q3
$53K Hold
146,402
﹤0.01% 312
2017
Q2
$56K Hold
146,402
﹤0.01% 288
2017
Q1
$66K Hold
146,402
﹤0.01% 275
2016
Q4
$56K Hold
146,402
﹤0.01% 279
2016
Q3
$39K Hold
146,402
﹤0.01% 302
2016
Q2
$35K Hold
146,402
﹤0.01% 314
2016
Q1
$17K Hold
146,402
﹤0.01% 313
2015
Q4
$16K Hold
146,402
﹤0.01% 306
2015
Q3
$28K Hold
146,402
﹤0.01% 287
2015
Q2
$102K Hold
146,402
﹤0.01% 266
2015
Q1
$99K Hold
146,402
﹤0.01% 280
2014
Q4
$116K Sell
146,402
-80,000
-35% -$54.6K ﹤0.01% 281
2014
Q3
$105K Hold
226,402
﹤0.01% 279
2014
Q2
$113K Sell
226,402
-3,000
-1% -$1.45K ﹤0.01% 274
2014
Q1
$73K Hold
229,402
﹤0.01% 338
2013
Q4
$78K Buy
229,402
+228,000
+16,262% +$276K ﹤0.01% 326
2013
Q3
$3K Hold
1,402
﹤0.01% 355
2013
Q2
$3K Buy
+1,402
New +$2.46K ﹤0.01% 349

Other funds holding GCVRZ

First Eagle Investment Management's GCVRZ Position: Q1 2018 in Review

First Eagle Investment Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2018, closing a stake of 146,402 shares — an estimated $56K sold.

First Eagle Investment Management first reported a position in GCVRZ in Q2 2013 and held it in 19 quarters. The position peaked at $116K in Q4 2014. 100 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2018.

  • First Eagle Investment Management reported no remaining Sanofi Contingent Value Rights position as of Q1 2018 after selling out during the quarter.
  • First Eagle Investment Management sold 146,402 Sanofi Contingent Value Rights shares in Q1 2018, an estimated $56K.
  • First Eagle Investment Management first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 19 quarters.
  • First Eagle Investment Management's Sanofi Contingent Value Rights position peaked at $116K in Q4 2014.
  • 100 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2018.

Based on First Eagle Investment Management's 13F filing for Q1 2018, filed 4 May 2018.